IL17hemmer

IL17hemmer is a colloquial or informal term used to refer to drugs that inhibit the activity of interleukin-17 (IL-17). Interleukin-17 is a pro-inflammatory cytokine that plays a significant role in the immune system's response to infections and in the pathogenesis of various autoimmune and inflammatory diseases. IL-17 is produced by several types of immune cells, primarily T helper 17 (Th17) cells, and it contributes to inflammation by promoting the production of other inflammatory molecules and recruiting immune cells to affected tissues.

Inhibiting IL-17 has emerged as a therapeutic strategy for a range of conditions where excessive or dysregulated IL-17 activity contributes to disease. These conditions often include psoriasis, psoriatic arthritis, ankylosing spondylitis, and other spondyloarthropathies. By blocking the action of IL-17, these "IL17hemmer" drugs can reduce inflammation, alleviate symptoms, and slow disease progression in affected individuals. Several biologic medications have been developed that target IL-17 or its receptor. These drugs are typically administered via injection or infusion and are often used when other treatments have not been sufficiently effective. The development of IL-17 inhibitors represents a significant advancement in the treatment of chronic inflammatory and autoimmune diseases.